These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-000411-25 A phase II trial and "scheduling finding" of cetuximab in combination with rapidly alternating chemo-radiation in unresectable,locally advanced, squamous cell carcinoma of the head and neck (HNC) not-yet-due
Ongoing 2004-002376-42 PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER not-yet-due
Ongoing 2005-005846-37 STUDY MULTICENTRIC PILOT OF CHEMOTHERAPY WITH CAPECITABINE, OXALIPLATIN LOHP IRINOTECAN Cpt-11 IN PATIENTS WITH Colorectal METASTATIC cancer not-yet-due
Ongoing 2006-001007-11 OPEN-LABEL, MULTICENTER, PHASE II STUDY OF FIRST- LINE BI-WEEKLY IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV (FOLFOXIRI) IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER... not-yet-due
Ongoing 2006-004478-29 DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND PH... not-yet-due
Ongoing 2007-002886-11 AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS B... not-yet-due
Ongoing 2007-002909-49 Neoadjuvant chemotherapy in patients affected by prostatic cancer locally advanced (non metastatic. Phase II study not-yet-due
Completed, but no date 2008-001537-10 A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER bad-data
Ongoing 2008-001763-11 LOW-DOSE METRONOMIC TEMOZOLOMIDE AND SORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: A PHASE II CLINICAL TRIAL WITH EVALUATION OF CLINICAL, BIOLOGIC AND PHARMACODYNAMIC EFFECTS OF THE C... not-yet-due
Ongoing 2008-003160-19 CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETROSP... not-yet-due
Ongoing 2009-013402-14 INduction chemoThERapy followed by CEtuximab Plus definiTive radiOtheRapy versus radiation plus cisplatin not-yet-due
Completed, but no date 2009-014556-29 PHASE II TRIAL OF FOLFOXIRI PLUS PANITUMUMAB AS FIRST-LINE TREATMENT FOR KRAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER bad-data
Ongoing 2009-017596-26 Terapia di II linea con Docetaxel + Lanreotide in pazienti con carcinoma prostatico metastatico ormonorefrattario e in progressione in corso di chemioterapia di I linea con Docetaxel. Studio di fase I... not-yet-due
Ongoing 2011-000840-70 INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS not-yet-due
Ongoing 2014-001126-15 A phase II single-arm study of cetuximab plus irinotecan not-yet-due
Ongoing 2014-004436-19 First-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab at progression versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at progression in firs... not-yet-due